Revolutionizing Huntington’s Disease Treatment: Breakthroughs in AAV-Mediated Gene Therapy
Cells · 2025
DOI: 10.3390/cells14191514 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Pedram Moeini Gavgani und 1 weiteren Autor:innen. Beteiligte Einrichtung: DNA & RNA Medicine Division, CIMA-Universidad de Navarra, 31008 Pamplona, Spain. Hauptthemen laut MEDLINE: Huntington Disease, Genetic Therapy, Dependovirus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 222 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Huntington’s Disease (HD) is an inherited neurodegenerative condition caused by an expansion of CAG repeats in the Huntingtin (HTT) gene, leading to a toxic form of the HTT protein. Despite advances in understanding the disease and developing symptomatic treatments, effective therapies for modifying its progression remain limited. Among emerging and novel treatments for central nervous system (CNS) disorders, gene therapy (GT), particularly using adeno-associated virus (AAV)-mediated gene delivery, holds great promise. Numerous preclinical and clinical trials are exploring the benefits of AAVs for treating neurodegenerative and genetic diseases. However, while widely used and investigated in rare and genetic disease treatment, AAVs’ potential for HD treatment remains underexplored. The absence of a comprehensive collection of previous reports, advancements, and methodologies regarding exclusively AAV-mediated GT for HD is notable and prompted us to address this gap. The current review compiles the available and emerging information regarding the application of AAVs in HD therapy, outlines the promise of this approach, and highlights the necessity of conducting further studies to achieve efficient HD treatment. The authors hope that the current review will guide further research to unlock the full potential of AAVs in treating HD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DNA & RNA Medicine Division, CIMA-Universidad de Navarra, 31008 Pamplona, Spain.
- Program of Immunology and Immunotherapy, CIMA-Universidad de Navarra, 31008 Pamplona, Spain.
- Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
Zitieren
APA
Gavgani, P. M., & García-Domínguez, M. (2025). Revolutionizing Huntington’s Disease Treatment: Breakthroughs in AAV-Mediated Gene Therapy. Cells. https://doi.org/10.3390/cells14191514
Vancouver
Gavgani PM, García-Domínguez M. Revolutionizing Huntington’s Disease Treatment: Breakthroughs in AAV-Mediated Gene Therapy. Cells. 2025. doi:10.3390/cells14191514
BibTeX
@article{Gavgani2025,
author = {Gavgani, Pedram Moeini and García-Domínguez, Mario},
title = {Revolutionizing Huntington’s Disease Treatment: Breakthroughs in AAV-Mediated Gene Therapy},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14191514}
}
EUVIMED